Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects.

Pharmacol Res Perspect · 2017 · PMC5461644 · PMID 28596840

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a possible trendno p-value reported

At follow‐up, 6 weeks after the last administration of ISIS 388626, a possible trend toward an increased urinary glucose excretion and increased fractional glucose excretion was observed in the treatment group compared to placebo.

also in 1,410 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.